Spyre Therapeutics, Inc. (SYRE), a company focused on inflammatory bowel disease on Monday said it entered into a deal for a private investment in public equity or PIPE financing for gross proceeds of around $180 million.
The company intends to use the proceeds from the PIPE financing, together with its existing cash, to fund its pipeline programs, and for general corporate purposes and working capital.
Spyre is selling 121,625 shares of its Series B non-voting convertible preferred stock at $1,480 per share.
The shares of Series B preferred stock are convertible into an aggregate of 4,865,000 shares. Each share of Series B preferred stock will automatically convert into 40 shares.
The PIPE financing, which is expected to be closed on or about March 20, included participation of both new and existing investors.
Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities, and LifeSci Capital are acting as joint placement agents for the PIPE financing.
SYRE was trading up by 4.72 percent at $47.51 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.